Skip to content

Evaluating the Effectiveness of Percutaneous Vertebroplasty and Retrolaminar Block for Osteoporotic Vertebral Compression Fractures

Clinical Observation of the Retrolaminar Block in Patients with Osteoporotic Vertebral Compression Fractures Undergoing Percutaneous Vertebroplasty

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600117226
Enrollment
Unknown
Registered
2026-01-21
Start date
2026-02-01
Completion date
Unknown
Last updated
2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporotic Vertebral Compression Fracture

Interventions

Traditional local anesthesia group,:Prior to the conclusion of the surgery, a posterior lamina injection of 15 mL of 0.95% normal saline was administered under C-arm guidance at the surgical segment.
retrolaminar block group:Prior to the conclusion of surgery, a posterior lamina nerve block was administered at the surgical segment under C-arm guidance, with an injection of 15 mL of 0.375% ropivaca

Sponsors

The First People’s Hospital of Guangyuan
Lead Sponsor

Eligibility

Sex/Gender
All
Age
60 Years to 90 Years

Inclusion criteria

Inclusion criteria: Age >=60 years, diagnosed with acute (duration =4 points, failed conservative treatment (bed rest, medication) after 2 weeks, American Society of Anesthesiologists (ASA) classification I–III, and informed consent obtained from the patient.

Exclusion criteria

Exclusion criteria: Presence of combined fractures in other locations or pathological fractures (e.g., tumor metastasis), severe vertebral compression (vertebral height loss >75%) or posterior vertebral wall incompetence, coagulation disorders (INR >1.4, platelet count <80×10^9/L), hypersensitivity to local anesthetics (ropivacaine) or opioid drugs, infection at the puncture site, severe cardiac, pulmonary, hepatic, or renal insufficiency, cognitive impairment or psychiatric disorders, inability to cooperate with pain assessment, history of chronic opioid use or drug addiction.

Design outcomes

Primary

MeasureTime frame
Resting and active (turning over) visual analog scale;

Secondary

MeasureTime frame
Cumulative consumption of flurbiprofen axetil within 48 hours postoperatively;Time of first ambulation;Postoperative hospital stay;The improvement rate of the Oswestry Disability Index (ODI) on preoperative day and postoperative days 1 and 3;Patient satisfaction scores;Complications Associated with Retrolaminar Block;Complications Associated with Percutaneous Vertebroplasty (PVP);

Countries

China

Contacts

Public ContactLiu Can

The First People’s Hospital of Guangyuan

lcdyx2014@126.com+86 188 1179 2808

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026